
|Articles|September 1, 2003
Reimbursement Achievable for Biologics in Psoriasis
The January FDA clearance of Biogen Inc.'s Amevive (alefacept) for the treatment of moderate-to-severe chronic plaque psoriasis officially ushered in the era of biologic treatments for dermatologists.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
2
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











